References
- 1. Rosendaal F. Venous thrombosis: amulticausal disease. Lancet. 1999;353(9159):1167-73.
- 2. Kujovich J. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16.
- 3. Rodger M, Wells PS. Diagnosis of pulmonary embolism. Thromb Res. 2001;103(6):225-38.
- 4. Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Colleman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Pa: Lippincott Williams and Wilkins; 2001. p. 975-1002. 2002.
- 5. Smith EB. Haemostatic risk factors for cardiovascular diseases. 1998;19:39-43.
- 6. Olié V, Zhu T, Martinez I, Scarabin P-Y, Emmerich J. Sex-specific risk factors for recurrent venous thromboembolism. Thromb Res. 2012;130(1):16-20.
- 7. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis. 2012;141(2):351-418.
- 8. Wilbur J, Shian B. Diagnosis of DVT, Am Fam Physician. 2012:86(10):913-9.
- 9. Komsa-Penkova R, Kovacheva- Kotseva K, Angelova S, Savov A, Semionova M. Selected methods of DNA analysis and clinical applications. Pleven: MU – Pleven; 2004.
- 10. Kwok S, Higuchi R. Avoiding false-positives with PCR. Nature. 1989;339(6221):237-8.
- 11. Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis: a meta-analysis. Thromb Haemost. 2007;97(6):907-13.
- 12. Ivanov P, Komsa-Penkova R, Ivanov Y, Ivanov I, Matkov O, Beshev L. [Polymorphism in 4G/5G in the plasminogen activator inhibitor-1 gene in patients with DVT]. Savremenna Medicina. 2009;60(2):35-9. Bulgarian
- 13. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000;101(1):67-70.
- 14. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001;104(25):3063-8.
- 15. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9(2):131-7.
- 16. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003;34:2822-8
- 17. Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE. Angiotensin I–converting enzyme and plasminogen activator inhibitor–1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol. 1999;34:1176-83.
- 18. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. 2000;101:67-70.
- 19. Argirios E, Tsantes A, Georgios K, Nikolopoulos B, Pantelis G, Bagos S, et al. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res. 2008;122:736-42
- 20. Komsa-Penkova R, Ivanov Y, Tonchev P, Ivanov P, Golemanov G, Kovacheva K, et al. Predisposition to thrombophilia and hypofibrinolysis in pulmonary embolism: analysis of inherited factors. J Boimed Clin Res. 201;6(2):73-81.
- 21. Saucedo R, Basurto L, Zarate A, Martínez C, Hernandez M, Galván R. Effect of Estrogen Therapy on Insulin Resistance and Plasminogen Activator Inhibitor Type 1 Concentrations in Postmenopausal Women. Gynecol Obstet Invest. 2007;64(2):61-4